Cargando…

Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up

PURPOSE: To assess the performance of the Xpert Bladder Cancer (BC) Monitor during the follow-up of patients with non-muscle invasive bladder cancer (NMIBC). METHODS: Patients with previously diagnosed NMIBC and followed up in clinical practice settings in two French urology departments between Sept...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cancel-Tassin, G., Roupret, M., Pinar, U., Gaffory, C., Vanie, F., Ondet, V., Compérat, E., Cussenot, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994915/ https://www.ncbi.nlm.nih.gov/pubmed/33770241 http://dx.doi.org/10.1007/s00345-021-03629-1

Ejemplares similares

Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma
por: Cussenot, Olivier, et al.
Publicado: (2013)

Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies)
por: Cancel-Tassin, Geraldine, et al.
Publicado: (2015)

The Genetic Complexity of Prostate Cancer
por: Compérat, Eva, et al.
Publicado: (2020)

Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive Bladder Cancer Recurrences: Could Cystoscopy Be Substituted?
por: Lozano, Fernando, et al.
Publicado: (2023)

Diagnostic value of Xpert(®) Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer: an update
por: D’Elia, Carolina, et al.
Publicado: (2021)

The Performance of the Xpert Bladder Cancer Monitor Test and Voided Urinary Cytology in the Follow-up of Urinary Bladder Tumors
por: Smrkolj, Tomaz, et al.
Publicado: (2020)

Longitudinal follow‐up and performance validation of an mRNA‐based urine test (Xpert(®) Bladder Cancer Monitor ) for surveillance in patients with non‐muscle‐invasive bladder cancer
por: Cowan, Barrett, et al.
Publicado: (2021)

Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under “Active Surveillance” for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study
por: Fasulo, Vittorio, et al.
Publicado: (2022)

Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow‐up of non‐muscle‐invasive bladder cancer: a blinded prospective multicentric study
por: Gontero, Paulo, et al.
Publicado: (2020)

PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers
por: Compérat, Eva, et al.
Publicado: (2021)

Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial)
por: Breyer, Johannes, et al.
Publicado: (2023)

Pooled analysis of Xpert Bladder Cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma
por: Liu, Ye-Ling, et al.
Publicado: (2021)

An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Comment on “Pooled analysis of Xpert bladder cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma”
por: Sharma, Gopal
Publicado: (2021)

The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT© Bladder Cancer Monitor and Narrow Band Imaging© Cystoscopy
por: Singer, Gad, et al.
Publicado: (2022)

Response to comment on “Pooled analysis of Xpert bladder cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma”
por: Xie, Yu-Fei, et al.
Publicado: (2022)

Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017
por: Pradère, Benjamin, et al.
Publicado: (2017)

Bladder Preservation for Muscle Invasive Bladder Cancer
por: Mirza, Arafat, et al.
Publicado: (2016)

Noninvasive multianalyte diagnostic assay for monitoring bladder cancer recurrence
por: Shore, Neal D, et al.
Publicado: (2012)

Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study
por: Vermeulen, S H, et al.
Publicado: (2015)

Deceptive Muscle Invasive Bladder Cancer Recurrence With Benign Biopsy Foci After Bladder Sparing Treatment
por: Xu, Chuanliang, et al.
Publicado: (2015)

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence
por: Zhang, Jianglei, et al.
Publicado: (2021)

Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
por: El-Taji, Omar M. S., et al.
Publicado: (2016)

Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer
por: Roperch, Jean-Pierre, et al.
Publicado: (2016)

Intravesical therapy for bladder cancer in the pandemic of Covid-19
por: Teoh, Jeremy Y. C., et al.
Publicado: (2020)

Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer
por: Quhal, Fahad, et al.
Publicado: (2021)

Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
por: Tholomier, Côme, et al.
Publicado: (2020)

Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis
por: Pones, Mario, et al.
Publicado: (2021)

Limited Value of Bladder Wash Cytology During Follow-Up of Patients With Non-muscle Invasive Bladder Cancer
por: Bieri, Uwe, et al.
Publicado: (2023)

Effectiveness of Early Radical Cystectomy for High-Risk Non-Muscle Invasive Bladder Cancer
por: Diamant, Elliott, et al.
Publicado: (2022)

Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
por: Katayama, Satoshi, et al.
Publicado: (2022)

Follow-up in non-muscle invasive bladder cancer: facts and future
por: Witjes, J. Alfred
Publicado: (2020)

Prostatic urethra recurrence after transurethral resection of bladder tumor (TURBT) for non‐muscle‐invasive bladder cancer (NMIBC)
por: Bilim, Vladimir, et al.
Publicado: (2022)

Letter to the Editor on the systematic review “Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer”
por: Roupret, Morgan, et al.
Publicado: (2023)

Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer
por: Zhu, Huier, et al.
Publicado: (2019)

Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guérin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic
por: Lenfant, Louis, et al.
Publicado: (2020)

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer
por: Rose, Tracy L., et al.
Publicado: (2016)

Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?
por: Smelser, Woodson Wade, et al.
Publicado: (2017)

AB007. Bladder-sparing treatments for muscle-invasive bladder cancer
por: Li, Shengwen, et al.
Publicado: (2017)

Bladder preservation in muscle-invasive bladder cancer: a comprehensive review
por: Hamad, Judy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_md50iogs1l1iogtd0hgd68ntsf